Sydney Lupkin

Patients in the trial had knee arthritis.

And researchers found that the drug also markedly reduced patients' knee pain.

Side effects for retitrutide included nausea, constipation, and vomiting.

Lilly said the results will be presented at a future medical meeting and published in a peer-reviewed journal.

Sydney Lepkin, NPR News.

We don't want the chaos that is out in the media.

in this courtroom.

Eli Lilly is the company behind blockbuster obesity drug Zepbound.

Now it's working on a next generation medicine.

Eli Lilly's experimental new drug is called retitrutide.

It's still being studied and hasn't yet been submitted to the Food and Drug Administration for approval, but new study results show that patients taking the highest dose of the drug lost an average of 72 pounds over 68 weeks, according to the company.

Patients in the trial had knee arthritis, and researchers found that the drug also markedly reduced patients' knee pain.

Side effects for retitrutide included nausea, constipation, and vomiting.

Lilly said the results will be presented at a future medical meeting and published in a peer-reviewed journal.

Sydney Lepkin, NPR News.

New drugs typically cost a lot more in the U.S.

than they do in other countries.

And the Trump administration has been announcing deals with drug companies to try to even the playing field.

Now the U.S.

has a deal with another country, the U.K.